Literature DB >> 2824064

The effects of human immunodeficiency virus recombinant envelope glycoprotein on immune cell functions in vitro.

M R Shalaby1, J F Krowka, T J Gregory, S E Hirabayashi, S M McCabe, D S Kaufman, D P Stites, A J Ammann.   

Abstract

The effect of human immunodeficiency virus (HIV) recombinant envelope glycoprotein 120 (rgp 120) on the functions of peripheral blood mononuclear cells (PBMC) in vitro was investigated. The results demonstrate that rgp 120 used at concentrations less than 1 microgram/ml has no significant effects on PBMC function in vitro. However, the addition of 1-20 micrograms/ml of rgp 120 significantly inhibits the tetanus toxoid-induced PBMC proliferative response in a dose-related manner as determined by [3H]thymidine incorporation. The data also show that rgp 120 (5 micrograms/ml) causes up to 70% reduction in the number of immunoglobulin G-secreting cells in pokeweed mitogen-stimulated PBMC cultures. Further, rgp 120 can selectively interact with the CD4a epitope of the CD4 helper cell membrane receptor. These results indicate that microgram per milliliter levels of rgp 120 can depress certain immune functions in vitro. The significance of these findings to the pathogenesis of immunodeficiency in HIV infection remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2824064     DOI: 10.1016/0008-8749(87)90108-0

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  14 in total

1.  The role of CD4+ lymphocytes in the activation of non-specific suppressor cells by antigen.

Authors:  H Stefanovic; C Izaguirre; L G Filion
Journal:  Immunology       Date:  1989-07       Impact factor: 7.397

2.  Inhibitory activity of HIV envelope gp120 dominates over its antigenicity for human T cells.

Authors:  F Manca; L Walker; A Newell; F Celada; J A Habeshaw; A G Dalgleish
Journal:  Clin Exp Immunol       Date:  1992-04       Impact factor: 4.330

Review 3.  B cell responses to HIV and the development of human monoclonal antibodies.

Authors:  J E Boyd; K James
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

4.  Regulation of the serine-base exchange enzyme system by CD4: effects of monoclonal antibodies, jacalin, interleukin 16 and the HIV membrane protein gp120.

Authors:  M J Dumaurier; C Pelassy; J P Breittmayer; C Aussel
Journal:  Biochem J       Date:  1998-01-01       Impact factor: 3.857

5.  Depletion of the surface CD4 molecule by the envelope protein of human immunodeficiency virus expressed in a human CD4+ monocytoid cell line.

Authors:  I Kawamura; Y Koga; N Oh-Hori; K Onodera; G Kimura; K Nomoto
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

6.  Changes in interleukin-2 and interleukin-4 production in asymptomatic, human immunodeficiency virus-seropositive individuals.

Authors:  M Clerici; F T Hakim; D J Venzon; S Blatt; C W Hendrix; T A Wynn; G M Shearer
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

7.  Immunological studies of the basis for the apathogenicity of simian immunodeficiency virus from African green monkeys.

Authors:  S G Norley; G Kraus; J Ennen; J Bonilla; H König; R Kurth
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

8.  HIV induces modulation of functionally important cellular antigens.

Authors:  M Wrightham; A Schimpf; T H Pennington; F Walker; H F Sewell
Journal:  Clin Exp Immunol       Date:  1991-07       Impact factor: 4.330

9.  Effects of interleukin 2 and large envelope glycoprotein (gp 120) of human immunodeficiency virus (HIV) on lymphocyte proliferative responses to cytomegalovirus.

Authors:  J Krowka; D Stites; J Mills; H Hollander; T McHugh; M Busch; L Wilhelm; L Blackwood
Journal:  Clin Exp Immunol       Date:  1988-05       Impact factor: 4.330

10.  Quantitation of antigen-specific immune responses in human immunodeficiency virus (HIV)-infected individuals by limiting dilution analysis.

Authors:  S Sabbaj; M F Para; R J Fass; P W Adams; C G Orosz; C C Whitacre
Journal:  J Clin Immunol       Date:  1992-05       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.